Company Analysis

Nurix Therapeutics, Inc. (NRIX)

Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Grade5.9
◀ Past 6.2● Present 5.7▶ Future 5.9
1 est.

The company now

Nurix Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Brisbane, CA. In its latest annual figures on file, for the fiscal year ended 2025-11-30, it reported revenue of $84 million and a loss of $264 million (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by product, fiscal 2025

ProductFiscal 2025Fiscal 2024Share of revenue
Collaboration Revenue$54.0M$54.5M64.3%
License Revenue$30.0Mn/a35.7%

As tagged in its annual report (Form 10-K, filed Jan 28, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton NRIX · research, not advice